StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Iovance Biotherapeutics's price to sales ratio was 11.3× on Nov 11, 2026, against 3.8× a year earlier. Over the last 2 years it ranged from 2.7× to 105.8×, with a median of 6.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202611.3×+7.1
2025Dec 31, 20254.2×−20.6
2024Dec 31, 202424.8×–

More Iovance Biotherapeutics figures

See a number that looks wrong?